LVW Advisors LLC Has $569,000 Stake in Bristol-Myers Squibb (NYSE:BMY)

LVW Advisors LLC cut its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 13.5% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,052 shares of the biopharmaceutical company’s stock after selling 1,571 shares during the period. LVW Advisors LLC’s holdings in Bristol-Myers Squibb were worth $569,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in BMY. Annex Advisory Services LLC increased its stake in shares of Bristol-Myers Squibb by 6.0% in the fourth quarter. Annex Advisory Services LLC now owns 6,796 shares of the biopharmaceutical company’s stock worth $384,000 after acquiring an additional 384 shares during the last quarter. Grove Bank & Trust grew its stake in Bristol-Myers Squibb by 14.9% in the fourth quarter. Grove Bank & Trust now owns 18,550 shares of the biopharmaceutical company’s stock valued at $1,049,000 after purchasing an additional 2,407 shares in the last quarter. Brady Martz Wealth Solutions LLC purchased a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth about $239,000. Clarius Group LLC lifted its holdings in shares of Bristol-Myers Squibb by 10.0% during the 4th quarter. Clarius Group LLC now owns 15,541 shares of the biopharmaceutical company’s stock valued at $879,000 after buying an additional 1,409 shares during the last quarter. Finally, Aaron Wealth Advisors LLC increased its holdings in Bristol-Myers Squibb by 2.5% in the fourth quarter. Aaron Wealth Advisors LLC now owns 90,400 shares of the biopharmaceutical company’s stock worth $5,113,000 after buying an additional 2,207 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Transactions at Bristol-Myers Squibb

In other news, SVP Phil M. Holzer sold 700 shares of the firm’s stock in a transaction on Monday, November 4th. The stock was sold at an average price of $55.62, for a total value of $38,934.00. Following the completion of the sale, the senior vice president now directly owns 11,760 shares in the company, valued at approximately $654,091.20. This trade represents a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Samit Hirawat purchased 1,830 shares of Bristol-Myers Squibb stock in a transaction that occurred on Friday, November 1st. The shares were bought at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the transaction, the executive vice president now owns 62,109 shares in the company, valued at $3,395,499.03. This represents a 3.04 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 0.09% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on BMY shares. TD Cowen boosted their target price on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. BMO Capital Markets upped their price target on Bristol-Myers Squibb from $57.00 to $61.00 and gave the stock a “market perform” rating in a research note on Tuesday, November 12th. Sanford C. Bernstein initiated coverage on Bristol-Myers Squibb in a research note on Thursday, October 17th. They issued a “market perform” rating and a $56.00 price objective on the stock. Jefferies Financial Group upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and increased their price target for the company from $63.00 to $70.00 in a report on Monday, December 16th. Finally, Bank of America restated a “neutral” rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a research note on Tuesday, December 10th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, four have issued a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $56.27.

Bristol-Myers Squibb Stock Down 0.0 %

Shares of BMY opened at $56.35 on Tuesday. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $61.08. The stock has a market cap of $114.30 billion, a price-to-earnings ratio of -15.70, a P/E/G ratio of 1.95 and a beta of 0.45. The company has a 50-day moving average price of $57.53 and a two-hundred day moving average price of $52.09. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.49 by $0.31. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The business had revenue of $11.89 billion for the quarter, compared to analyst estimates of $11.26 billion. During the same quarter in the previous year, the firm earned $2.00 EPS. Bristol-Myers Squibb’s quarterly revenue was up 8.4% on a year-over-year basis. Equities analysts predict that Bristol-Myers Squibb will post 0.93 EPS for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be paid a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 4.40%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. The ex-dividend date of this dividend is Friday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio is currently -69.08%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.